Part XII · HER2-positive disease · Chapter 71

Early triple-positive disease

--- id: BC-840 title: "Early triple-positive disease" subtitle: "Most of HER2-positive breast cancer, treated on subgroups of trials designed for something else." status: drafted updated: 2026-09-26 ---

1 · Why hormone receptor-positive HER2-positive disease behaves as its own entity

This chapter covers early hormone receptor-positive, HER2-positive breast cancer as a disease in its own right. The word triple-positive is clinical shorthand rather than a guideline category. It names the intersection of three separate assays, each with its own threshold and its own reproducibility, and Receptor assessment and the measurement problem sets those out.

The intersection is not a small corner. In APHINITY, the adjuvant pertuzumab trial, the hormone receptor-positive group was the clear majority. The population column of the table below records that split. Whatever the exact figure in an unselected population, this is most of HER2-positive breast cancer rather than a fraction of it.

Four things make it behave differently, each of them developed in a section below.

Pathological complete response rates are consistently lower than in hormone receptor-negative HER2-positive disease, across regimens and across two decades Lower pathological complete response rates and what that does to the post-neoadjuvant decision.

Pathological complete response also carries less prognostic information here. In a pooled analysis of seven randomised trials it was associated with disease-free survival in HER2-positive non-luminal disease and was not associated with it in luminal B HER2-positive disease¹.

The two dependencies run on different clocks, because HER2-directed therapy finishes at one year while endocrine therapy runs for five to ten. The late recurrence hazard described in Late recurrence risk and surveillance implications applies here as it does to any other hormone receptor-positive group.

Almost everything known about the entity comes from hormone receptor subgroups of trials designed for HER2-positive disease as a whole Subgroup evidence from the HER2 trials, and its limits.

What this chapter leaves to neighbours. The HER2-directed neoadjuvant backbone belongs to Neoadjuvant therapy, and adjuvant and post-neoadjuvant HER2-directed therapy to Adjuvant and post-neoadjuvant therapy. Choice and duration of adjuvant endocrine therapy belongs to Adjuvant endocrine therapy. The metastatic setting belongs to Metastatic triple-positive disease. What is left here is the reasoning that makes this group its own entity rather than a subgroup of two others.

Each section below opens with the question its trials were built to answer, taken from the [Chapter Stories](stories.html) map, and closes with a table filtered on that same question. The story says what was being looked for and what the design cannot settle. The table says what else is in the cell. The prose argues the decision.

That table is the map of the chapter rather than a menu of options. It holds eight distinct questions, and the reason two rows disagree is usually that they were asked different ones.

Five trials built the backbone that everything else in the table sits on. HERA, NSABP B-31/N9831 and BCIRG-006 put adjuvant trastuzumab against chemotherapy alone, and NOAH did the same before surgery. FinHer did it with nine weeks of trastuzumab, inside a trial comparing two chemotherapy regimens. None of the five was designed to say anything about the oestrogen receptor.

Five asked how long that backbone has to run. HERA carried a two-year arm, PERSEPHONE and PHARE tested six months, and Short-HER and SOLD tested nine weeks. Why those four do not agree with one another is argued in Subgroup evidence from the HER2 trials, and its limits.

Eleven asked what should be added to that backbone, or exchanged for part of it. NeoALTTO, NeoSphere, NSABP B-41, CALGB 40601, PEONY and PHEDRA added a second HER2-directed agent before surgery. IMpassion050 added a checkpoint inhibitor instead, and DESTINY-Breast11 exchanged the anthracycline for a conjugate ahead of the same triplet. ALTTO, APHINITY and ExteNET added an agent after surgery.

Four asked which chemotherapy belongs underneath the HER2-directed treatment. TRYPHAENA and TRAIN-2 both removed the anthracycline, the first as a cardiac safety study and the second as a randomised efficacy comparison. HELEN-006 set weekly nab-paclitaxel against docetaxel with carboplatin under the same dual blockade. neoCARHP kept the taxane and dual blockade in both arms and asked whether the carboplatin was needed at all.

Three substituted an antibody-drug conjugate for the cytotoxic chemotherapy. KRISTINE did it before surgery, KAITLIN after it, in place of the taxane that followed an anthracycline, and WSG-ADAPT-TP did it in a twelve-week window confined to this population.

Two asked how little a small node-negative tumour needs. APT gave twelve weeks of paclitaxel with trastuzumab in a single group, which ATEMPT then used as the comparator for a conjugate.

Eleven tried to manage without a full course of cytotoxic chemotherapy. TBCRC 006, TBCRC 023, PAMELA, PerELISA, WSG TP-II and TOUCH relied on endocrine therapy to hold the second pathway instead. PHERGain, PHERGain-2, CompassHER2 pCR, DAPHNe and TRAIN-3 let a response on imaging or at surgery decide how much was given, which is the argument Chemotherapy omission and the de-escalation questions specific to this group carries.

Three asked what to do when the specimen still contains invasive disease, of which KATHERINE and DESTINY-Breast05 have reported and CompassHER2 RD has not.

Only four trials in the table enrolled this population and no other. The rest contain it, which is the fact Subgroup evidence from the HER2 trials, and its limits is about.

The metastatic trials are set out in Metastatic therapy from first line onwards and Metastatic triple-positive disease and are not argued here. They are worth reading once, because they show what the same biology is allowed to do when the disease is incurable. TAnDEM and EGF30008 established that adding HER2 blockade to an aromatase inhibitor delays progression. The second of those enrolled regardless of HER2 status and made the HER2-positive group its primary analysis. PERTAIN then added a second antibody to that pair. SYSUCC-002 went further and tested endocrine therapy against chemotherapy as the partner for trastuzumab, on a non-inferiority design. PATINA added a CDK4/6 inhibitor to maintenance endocrine and HER2-directed therapy. It is the one trial in that table built on the convergence of the two receptors on the cell cycle. H0648g, MARIANNE, PERUSE, PHILA and HER2CLIMB-05 enrolled HER2-positive disease whatever its receptor status, and Metastatic therapy from first line onwards argues them.

CLEOPATRA and DESTINY-Breast09 sit in the same table for a different reason. Both enrolled HER2-positive disease of any receptor status and neither treats the oestrogen receptor as a target. The contrast is the point. In advanced disease the endocrine axis is something to aim at, and the cytotoxic is negotiable. In early disease nobody has run the equivalent trial.

2 · Reciprocal cross-talk and what it predicts for treatment

The mechanism is set out in ER and HER2 cross-talk, the bidirectional plane and Estrogen receptor signaling and endocrine resistance and is not restated. The short form is that the two pathways regulate each other in both directions, so blocking one raises traffic on the other. This section is about what that predicts in clinic.

It predicts that single-axis therapy selects for the other axis. Oestrogen receptor signalling is upregulated as an adaptive survival mechanism in HER2-positive tumours under anti-HER2 treatment⁵⁷. A tumour carrying both receptors therefore has an escape route that a receptor- negative one does not, which is the direct handoff from Resistance to antibodies, tyrosine kinase inhibitors, and conjugates. The clinical form of that prediction is simple. HER2 blockade without endocrine therapy should underperform here, as should endocrine therapy given without HER2 blockade.

It predicts that the two blockades should be given together rather than in sequence. Every gap between them is a window in which the escape route is open. The prediction is clean and the supporting randomised evidence in the adjuvant setting does not exist Endocrine therapy alongside HER2 blockade in the adjuvant setting.

It predicts a lower complete response rate. If the oestrogen receptor supplies a survival route that HER2-directed therapy does not close, then eradication should be less frequent when the receptor is present. That is what the neoadjuvant trials show Lower pathological complete response rates and what that does to the post-neoadjuvant decision.

It predicts that endocrine sensitivity should be measurable early and should matter. In PerELISA, a fall in Ki67 after two weeks of letrozole selected a group treated to surgery without chemotherapy²¹. A two-week endocrine response was being used to predict the result of a HER2-directed regimen, which only makes sense if the pathways are coupled.

It predicts convergence on the cell cycle. Both axes end at the same restriction point Cell cycle regulation, which is the rationale for PATINA and is developed in CDK4/6 inhibition with HER2 blockade.

3 · Lower pathological complete response rates and what that does to the post-neoadjuvant decision

The observation is unusually consistent, and it is a finding about the class rather than about any member of it. Wherever the receptor split is reported, response is lower in the receptor-positive stratum. It holds for a taxane with one antibody, for a taxane with an antibody and a tyrosine kinase inhibitor, and for a taxane with two antibodies. It holds for a conjugate substituted for the taxane. It holds in both arms of neoCARHP, with carboplatin and without it⁵. It holds in CompassHER2 pCR, the largest modern cohort given a taxane with dual blockade. Intensifying the HER2 blockade raises response in both strata and does not close the distance between them. Twenty years of drug development have moved the level and left the gradient alone, which is what makes it a property of the disease.

The trials in that table are not disagreeing about the gap. They are measuring different things. Three sources of variation account for most of the spread, and none of them is the drug.

The first is the endpoint. Some of these trials scored the breast alone and some the breast and the axilla. That convention costs more here than elsewhere, because low-volume residual disease concentrates in receptor-positive tumours. TBCRC 006 found residual ypT1a-b disease in a third of its receptor-positive cases and in a small fraction of its receptor-negative ones. Where the line between a complete response and a near-complete one is drawn therefore changes the size of the gap it produces. That is measurement rather than biology.

The second is the comparator. NOAH, NeoALTTO, NeoSphere, TRYPHAENA, TRAIN-2, DESTINY-Breast11, NSABP B-41, CALGB 40601, PEONY, PHEDRA, HELEN-006, neoCARHP and IMpassion050 added, exchanged or removed agents while keeping a cytotoxic backbone. KRISTINE, WSG-ADAPT-TP, WSG TP-II and TOUCH took the cytotoxic away. TBCRC 006, TBCRC 023, PAMELA, PHERGain, PHERGain-2, CompassHER2 pCR, DAPHNe and TRAIN-3 reported response without testing it against a randomised cytotoxic comparator. Two response rates from those three designs are not the same quantity.

The third is what was measured on the pretreatment biopsy. PerELISA found that the receptor-positive tumours which clear are largely the ones called HER2-enriched. PAMELA found the same split in a cohort that admitted any receptor status. That is a signature assay run on a single core, and it classifies the core rather than the tumour. Hormone receptor status was a stratification factor or a reporting subgroup in these trials and was randomised nowhere, so the two strata differ in more than the receptor.

Now put the lower response rate next to the second finding, because the combination is what matters. Complete response was not associated with disease-free survival in luminal B HER2-positive disease in the pooled German analysis, while it was strongly associated with it in non-luminal HER2-positive disease¹. In this subtype the endpoint is both rarer and less informative.

The consequence falls on the post-neoadjuvant decision, where KATHERINE and DESTINY-Breast05 both assign escalation on the presence of residual invasive disease. Those two are the load-bearing trials for this section even though neither is in its table. KATHERINE randomised against trastuzumab, which is what the clinic would otherwise have given. Its survival update is the only mature overall survival result in the post-neoadjuvant record. DESTINY-Breast05 then moved the comparator to the older conjugate, in a population that also had to carry nodal disease at surgery or inoperable disease at diagnosis. They are a chain and not a disagreement. More triple-positive patients are routed into that chain by a trigger that carries less prognostic information than it does in receptor-negative disease.

That is not an argument against escalating, but an argument about what the trigger means. The distinction is the one made in Response-adapted and de-escalation designs. A response-adapted trial demonstrates that a population defined by residual disease benefits from a specific drug. It requires neither that the defining measure be prognostic nor that a regimen producing more complete responses produce longer survival.

Three things the table cannot show are worth naming. It has no column for the volume of residual disease, which is the axis on which this population actually differs. It has no column for what was given after surgery, and in most of these protocols that was decided by the specimen. And two of its most relevant rows cannot yet answer the question they were built for. DESTINY-Breast11 reports the most recent neoadjuvant response gain in the table on event-free survival data that are 4.5% mature. CompassHER2 pCR is the largest modern cohort in this population. Its primary endpoint is recurrence-free survival among the patients who reached a complete response. That endpoint has not reported.

4 · Endocrine therapy alongside HER2 blockade in the adjuvant setting

Every patient in this chapter receives both treatments. The question is whether they should overlap, which no randomised trial in the adjuvant setting has answered.

The mechanistic case for overlapping them is the one in Reciprocal cross-talk and what it predicts for treatment. Oestrogen receptor signalling rises under anti-HER2 pressure⁵⁷, so the months between finishing HER2-directed therapy and starting endocrine therapy are months in which the escape route is unopposed. On that reasoning the two should start as close together as the chemotherapy schedule allows.

The case against is practical rather than biological, because nobody has shown harm from concurrent administration and nobody has shown benefit either. Aromatase inhibitor arthralgia, tamoxifen symptoms and trastuzumab infusions accumulate in the same weeks. Most of the adherence that is ever lost is lost in that first year Adherence, toxicity, and the gap between prescribed and taken.

What the neoadjuvant trials contribute is limited but real. In WSG-ADAPT-TP, adding endocrine therapy to twelve weeks of trastuzumab emtansine changed the complete response rate hardly at all. The conjugate itself accounted for a large difference against trastuzumab with endocrine therapy³¹. In TBCRC 006, letrozole was given concurrently with dual HER2 blockade throughout, on an explicit hypothesis that blocking both receptors was required³⁸. Neither trial isolates the contribution of timing, because neither randomised it.

Two practical points sit outside the trials. Endocrine therapy in this group runs long after HER2-directed therapy has finished. The late recurrence hazard in Late recurrence risk and surveillance implications is therefore the dominant long-term risk. Extended duration is decided on the same grounds as in HER2-negative disease Extended adjuvant therapy and the shape of the late benefit. And in the metastatic setting, receipt of endocrine therapy at all has been associated with better survival in this subtype in a real-world cohort⁵⁹. That is an association in advanced disease and not a randomised comparison in early disease, but the direction is consistent with the mechanism.

5 · Chemotherapy omission and the de-escalation questions specific to this group

This is the live de-escalation question. It is more live here than in receptor-negative disease for one reason. A triple-positive tumour has a second systemic therapy that works, which a receptor-negative one does not.

Seven trials in the table agree on one thing. A chemotherapy-free regimen clears disease in a minority of receptor-positive tumours, and that minority is real rather than anecdotal. They also agree, without having been designed to, on what governs the size of it. In WSG-ADAPT-TP the response rate tracked what carried the payload and not what was added alongside. Adding endocrine therapy to the conjugate changed the rate hardly at all, while replacing the conjugate with a bare antibody on the same endocrine therapy cut it to a fraction. TBCRC 023 points the same way from the other direction, since doubling the duration of chemotherapy-free dual blockade raised response in the receptor-positive subgroup rather than the receptor-negative one.

What separates these seven is evidentiary status, not drug. TBCRC 006 and PAMELA are single-arm windows. TBCRC 023 combined a phase II design in its experimental arm with a pick-the-winner design. It was not powered to compare its two durations, so its duration gap is a numerical difference with no test behind it. WSG-ADAPT-TP randomised the partner drug rather than the strategy. PerELISA randomised nothing and allocated on a marker. Only WSG TP-II and TOUCH put a chemotherapy-free arm against a cytotoxic one, and TOUCH was built to test a gene signature rather than to compare the arms. Its two response rates landed in the same place, which is a description and not a demonstration of equivalence, because no non-inferiority margin was ever set.

NA-PHER2 is the trial a reader will not find in that table, and the reason is a convention worth stating. An evidence table carries the record a decision rests on, and a single-arm exploratory study is not part of that record. It has coprimary endpoints of the change in proliferation at two weeks and at surgery and the change in apoptosis. Proliferation collapsed within two weeks of the chemotherapy-free combination and had risen again by surgery. Apoptosis fell over the same interval rather than rising. That is a statement about target engagement and it belongs beside its question rather than beside a randomised phase III.

WSG TP-II is the trial to read closely, because its design explains both its result and its limits. Substituting endocrine therapy for the weekly taxane more than halved the complete response rate. Five-year overall survival was nonetheless close to complete in both arms. The invasive disease-free survival estimates did not follow the response gap either, on an interval around the taxane arm that runs from 55.6% to 100%. That width is a statement about the size of the trial rather than about the treatments. The reason the arms converge is in the protocol rather than in the biology. Chemotherapy was mandatory after residual disease, so most of the endocrine arm received it anyway. The trial is consistent with a response-guided strategy being safe. It does not demonstrate that chemotherapy can be omitted, which is a different claim.

The selection tools are the weak point, and they fail in three different ways. A two-week Ki67 threshold and a PET metabolic response threshold are continuous measurements converted into a gate, and the reproducibility problem set out in Ki67, PEPI and response measures for a setting where pCR fails applies directly to the first. Allocation also confounds them. In PerELISA the molecular non-responders were sent to paclitaxel, so their higher response rate measures the paclitaxel rather than the marker. The baseline markers were never randomised either. An intrinsic subtype call in PAMELA, and the prospective two-site HER2 scoring in Neoadjuvant T-DM1-pertuzumab HER2-heterogeneity study, say who responds and not who needed the chemotherapy that was withheld. Heterogeneity in particular is a sampling convention rather than a property of the disease, and only 16 of 157 evaluable tumours met the definition. Exactly one marker in this literature was tested as a treatment interaction rather than as a prognostic split, the E2F signature in TOUCH, and it showed none.

The general shape of the problem is what the table cannot hold. Demonstrating omission requires showing that events did not accumulate, which needs more patients, longer follow-up and a non-inferiority margin somebody has to justify Designing de-escalation trials and the non-inferiority margin problem. No trial confined to early triple-positive disease has been built at that size. The one trial that tested a marker as an interaction enrolled postmenopausal patients with a median age of 69. That is narrower than the group the strategy is offered to.

6 · Subgroup evidence from the HER2 trials, and its limits

Almost every statement made in this chapter rests on a hormone receptor subgroup of a trial powered for HER2-positive disease as a whole. That is worth saying explicitly rather than leaving implicit, and Clinical trials and evidence interpretation sets the standard this section is held to.

Start with what the design does well. Randomisation was never done on the receptor. It balanced everything else inside each receptor stratum, so a receptor subgroup of a randomised trial remains a randomised comparison of the treatments that trial gave. Some of these trials, ExteNET among them, stratified randomisation on hormone receptor status as well, which makes the strata better behaved still. Stratification supplies neither power nor a randomised comparison for the question of whether receptor status modifies the treatment effect. In none of the reported trials in this table did a receptor subgroup reverse the direction of the trial's own answer.

Six rows do not speak to the receptor at all, and saying so is part of reading the table. HERA, NSABP B-31/N9831 and BCIRG-006 asked whether adjuvant trastuzumab works. They answered it in the same direction in every subgroup they examined. FinHer asked the same question of nine weeks of trastuzumab, in the 232 HER2-positive patients of a chemotherapy trial⁴⁴. ALTTO asked whether lapatinib adds to trastuzumab and found nothing that cleared its own revised threshold. That is a verdict on one tyrosine kinase inhibitor rather than on dual blockade, and the pertuzumab question was asked separately. CompassHER2 RD has not reported, and its eligibility is the subject of Unresolved questions and what reads out next.

The four duration trials look like the sharpest disagreement in the table and are the clearest case of divergence by design. PERSEPHONE declared non-inferiority for six months. PHARE tested the same six months and could not. Short-HER and SOLD tested nine weeks and could not either. The four used four different margins, a hazard ratio of 1.15, of 1.29 and of 1.3, and three percentage points of four-year disease-free survival. PHARE also randomised every patient several months into treatment rather than at the start. PERSEPHONE randomised some patients before trastuzumab began and others after it had started. Four margins and two durations produce four answers about study design and one answer about trastuzumab. No shorter schedule has displaced the year.

ExteNET is the one place in the table where the receptor looks as though it matters. The benefit of extended neratinib concentrated in hormone receptor-positive disease, and a final analysis of that subgroup exists⁶⁰. The mechanism section above supplies a reason to believe it. The trial's own eight-year overall survival comparison found nothing, in either direction, which is the endpoint this chapter is spending five to ten years of endocrine therapy on. A subgroup with a mechanism behind it is still a subgroup.

APHINITY is the instructive case for the general problem. The hormone receptor-positive and receptor-negative subgroup hazard ratios for adjuvant pertuzumab differ in point estimate and overlap substantially in interval⁶¹. The defensible reading is that nothing in those data distinguishes the two groups. The common reading, that pertuzumab works better in triple-positive disease, requires an interaction the trial did not demonstrate. The axis that did separate in that trial was nodal status rather than receptor status. A later exploratory subanalysis went further and located the largest benefit in a receptor-positive subset defined by HER2 expression⁶². A subanalysis of that kind generates a hypothesis rather than testing one.

Two rows carry a negative result that is more useful than it looks. KAITLIN substituted a conjugate for the taxane after an anthracycline in high-risk disease, and ATEMPT substituted it for the whole regimen in stage I disease. KAITLIN found no invasive disease-free survival difference against the taxane arm. ATEMPT was randomised three to one and was never sized to rank the two on outcome. On its other co-primary endpoint it failed to lower clinically relevant toxicity against the taxane comparator. Neither trial gave a reason to move. The same answer at both ends of the risk range is worth more than either trial alone. It is why APT rather than a conjugate remains the reference regimen for a small tumour.

The trial the decision rests on for a patient with residual disease is KATHERINE, for the same reason as in Lower pathological complete response rates and what that does to the post-neoadjuvant decision. It is the randomised comparison against what the clinic would otherwise do. It is also the only post-neoadjuvant trial in this table with a mature overall survival result. DESTINY-Breast05 raises the comparator and reports survival that is immature at its primary analysis.

Now the ceiling on the direct evidence. Four trials in the whole record enrolled early triple-positive disease and nothing else, and they enrolled 375, 207, 147 and 64 patients^31,8,9,21. None of them is in this table, because all four are neoadjuvant. Every adjuvant and post-neoadjuvant decision in this chapter is therefore made on a subgroup.

The asymmetry that follows is worth naming. Escalation decisions in this group rest on large randomised trials whose populations included it, which is a reasonable basis. De-escalation decisions rest on small trials designed for it, which is a weaker basis for a stronger claim. Practice has been more willing to de-escalate on the second than to question the first.

Three columns this table will never have. None of these trials reports overall survival within the hormone receptor-positive stratum as a tested comparison. None randomised when endocrine therapy should start relative to the HER2-directed year, which is the decision Endocrine therapy alongside HER2 blockade in the adjuvant setting is about. And the duration trials read disease-free survival at four and five years, in a group whose recurrence hazard is still running at ten Late recurrence risk and surveillance implications.

7 · Unresolved questions and what reads out next

The largest gap is an absence rather than a pending readout.

CompassHER2 RD tests escalation of post-neoadjuvant treatment for residual HER2-positive disease. Its eligibility is restricted to high-risk residual disease, defined as oestrogen receptor-negative or node-positive¹⁷. Receptor-positive, node-negative residual disease is therefore outside it. That is a large part of the triple-positive residual population, and precisely the group in which Lower pathological complete response rates and what that does to the post-neoadjuvant decision argues that residual disease is least informative about risk. The trial that would settle what to do with them is not running.

The other two trials in the table were built to test the opposite move. Both will read out a recurrence endpoint at three years. CompassHER2 pCR asks whether a complete response after a taxane with dual blockade licenses stopping there, measured as recurrence-free survival among the patients who reached one. PHERGain-2 asks the same of a chemotherapy-free course in node-negative tumours of 5 to 30 mm, with a recurrence-free interval outstanding alongside a quality-of-life endpoint that has reported. Between them they will say what a complete response in this subtype is worth, which is the question Lower pathological complete response rates and what that does to the post-neoadjuvant decision shows nobody can currently answer.

Two further readouts will change something. Overall survival from DESTINY-Breast05 will show whether the invasive disease-free survival gain in residual disease converts into longer life. Its population was assembled on residual disease with nodal involvement at surgery or inoperable disease at diagnosis, in which this chapter's group is over-represented for the reasons given in Lower pathological complete response rates and what that does to the post-neoadjuvant decision. And the adjuvant question raised by PATINA has no early-disease trial behind it. Whether CDK4/6 inhibition belongs in early triple-positive disease is unasked rather than unanswered CDK4/6 inhibition with HER2 blockade.

Two questions will probably never be answered directly. Concurrent against sequential endocrine therapy alongside HER2 blockade would need a large trial for a difference nobody expects to be large Endocrine therapy alongside HER2 blockade in the adjuvant setting. Chemotherapy omission in an unselected triple-positive population would need a non-inferiority trial whose margin would be hard to justify to a patient Designing de-escalation trials and the non-inferiority margin problem.

What a reader should take from that list is a calibration rather than a plan. This chapter describes the best-treated common subtype in breast cancer. It is also the one whose treatment rests most heavily on inference from populations assembled to answer a different question.

References

All 62 references

1. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012 30:1796-1804. PMID 22508812
2. Tung N, Zhao F, DeMichele A, et al. Pathologic complete response (pCR) rate and predictors of response to taxane, trastuzumab, and pertuzumab in HER2-positive breast cancer: secondary analyses of EA1181/CompassHER2 pCR. J Clin Oncol 2026. PMID 42623567
3. Loibl S, Park YH, Shao Z, et al. Trastuzumab deruxtecan in residual HER2-positive early breast cancer. N Engl J Med 2026 394:845-857. PMID 41370739
4. Harbeck N, Modi S, Pusztai L, et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Ann Oncol 2026 37:166-179. PMID 41130363
5. Gao HF, Ye GL, Lin Y, et al. Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial. J Clin Oncol 2026 44:1587-1596. PMID 41576297
6. Garrigós L, Ruiz-Borrego M, Pérez-García JM, et al. A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study. Ann Oncol 2026 37:837-848. PMID 42097893
7. Louis FM, et al. MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study. Lancet Oncol 2026 27:349-360. PMID 41713473
8. Gluz O, Nitz UA, Christgen M, et al. Survival analysis of the WSG TP-II trial: neoadjuvant trastuzumab and pertuzumab plus endocrine therapy versus chemotherapy in HR+/HER2+ early breast cancer. J Clin Oncol 2026. PMID 42150145
9. Malorni L, Tyekucheva S, Gombos A, et al. Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR-positive/HER2-positive early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). Ann Oncol 2025 37:194-205. PMID 41109527
10. Chen XC, et al. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial. Lancet Oncol 2024 26:27-36. PMID 39612919
11. Pérez-García JM, Cortés J, Ruiz-Borrego M, et al. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial. Lancet 2024 403:1649-1659. PMID 38582092
12. Waks AG, et al. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer 2022 8:63. PMID 35538105
13. Huober J, et al. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol 2022 40:2946-2956. PMID 35763704
14. Krop IE, Im SA, Barrios C, et al. Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer: the phase III KAITLIN study. J Clin Oncol 2022 40:438-448. PMID 34890214
15. Wu J, et al. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med 2022 20:498. PMID 36575513
16. Tolaney SM, Tayob N, Dang C, et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol 2021 39:2375-2385. PMID 34077270
17. O'Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol 2021 17:4665-4676. PMID 34636255
18. van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol 2021 7:978-984. PMID 34014249
19. Shao Z, et al. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol 2020 6:e193692. PMID 31647503
20. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019 380:617-628. PMID 30516102
21. Guarneri V, Dieci MV, Bisagni G, et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann Oncol 2019 30:921-926. PMID 30778520
22. Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019 393:2599-2612. PMID 31178152
23. Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019 393:2591-2598. PMID 31178155
24. Rimawi MF, Niravath P, Wang T, et al. TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. Clin Cancer Res 2019 26:821-827. PMID 31662331
25. Hurvitz SA, Martin M, Symmans WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2018 19:115-126. PMID 29175149
26. Conte P, Frassoldati A, Bisagni G, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol 2018 29:2328-2333. PMID 30219886
27. Joensuu H, Fraser J, Wildiers H, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol 2018 4:1199-1206. PMID 29852043
28. von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017 377:122-131. PMID 28581356
29. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 2017 389:1195-1205. PMID 28215665
30. Llombart-Cussac A, Cortes J, Pare L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA). Lancet Oncol 2017 18:545-554. PMID 28238593
31. Harbeck N, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer: final analysis of the West German Study Group ADAPT HER2-positive/hormone receptor-positive phase II randomized trial of 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy versus trastuzumab plus endocrine therapy. J Clin Oncol 2017 35:3046-3054. PMID 28682681
32. Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization trial. J Clin Oncol 2016 34:1034-1042. PMID 26598744
33. Carey LA, Berry DA, Cirrincione CT, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. J Clin Oncol 2016 34:542-549. PMID 26527775
34. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016 17:367-377. PMID 26874901
35. Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015 372:134-141. PMID 25564897
36. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014 32:3744-3752. PMID 25332249
37. Robidoux A, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013 14:1183-92. PMID 24095300
38. Rimawi MF, Mayer IA, Forero A, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013 31:1726-1731. PMID 23569315
39. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013 24:2278-2284. PMID 23704196
40. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012 379:633-640. PMID 22257673
41. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012 13:25-32. PMID 22153890
42. Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011 365:1273-1283. PMID 21991949
43. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010 375:377-384. PMID 20113825
44. Joensuu H, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 354:809-20. PMID 16495393
45. Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med 2026 394:551-562. PMID 41160818
46. Metzger O, Mandrekar S, Goel S, et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med 2026 394:451-462. PMID 41604639
47. Dieras V, et al. HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. J Clin Oncol 2025 44:1597-1607. PMID 41369677
48. Arpino G, et al. Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer: PERTAIN Final Analysis. Clin Cancer Res 2023 29:1468-1476. PMID 36716289
49. Ma F, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ 2023 383:e076065. PMID 37907210
50. Hua X, et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clin Cancer Res 2022 28:637-645. PMID 34810217
51. Miles D, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol 2021 32:1245-1255. PMID 34224826
52. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020 21:519-530. PMID 32171426
53. Perez EA, et al. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J Clin Oncol 2016 35:141-148. PMID 28056202
54. Johnston S, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009 27:5538-46. PMID 19786658
55. Kaufman B, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009 27:5529-37. PMID 19786670
56. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001 344:783-792. PMID 11248153
57. Giuliano M, et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res 2015. PMID 26015514
58. Metzger Filho O, Viale G, Stein S, et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov 2021 11:2474-2487. PMID 33941592
59. Carausu M, et al. Association of endocrine therapy for HR+/ERBB2+ metastatic breast cancer with survival outcomes (ESME real-world cohort). JAMA Netw Open 2022. PMID 36520434
60. Chan A, et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer 2020 21:80-91.e7. PMID 33183970
61. Piccart M, Procter M, Fumagalli D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up. J Clin Oncol 2021 39:1448-1457. PMID 33539215
62. Agostinetto E, Gentile G, Samy F, et al. The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial. J Natl Cancer Inst 2026 118:1504-1513. PMID 41934626